medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Maternal obesity and metabolic disorders associate with congenital heart defects in the offspring: a systematic review

Gitte Hedermann*[1], Paula L Hedley[1], Ida N Thagaard[1,2], Lone Krebs[3,4], Charlotte Kvist Ekelund[4,5], Thorkild IA Sørensen[6,7], Michael Christiansen[1,8]

[1] Department for Congenital Disorders, Danish National Biobank and Biomarkers, Statens Serum Institut, Copenhagen, Denmark

[2] Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

[3] Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Amager and Hvidovre Hospital, Copenhagen, Denmark

[4] Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

[5] Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

[6] Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark

[7] The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[8] Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Keywords: Obesity; diabetes mellitus; hypertension; congenital heart defects

Running title: Maternal metabolic disorders and foetal CHDs

Acknowledgements: Thank you to the researchers who readily provided supplementary information. This research has been conducted using the Danish National Biobank resource supported by the Novo Nordisk Foundation.

An earlier version of the article is available at a preprint server, MedRxiv (DOI: https://doi.org/10.1101/2020.06.25.20140186).

Funding information: This study was supported by The Danish Children Heart Foundation (18-R109-A5193-26043), The A.P. Moller Foundation (19-L-0096), and Aase and Ejnar Danielsen's Foundation (19-10-0493). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Corresponding author*: Department for Congenital Disorders

Danish National Biobank and Biomarkers

Statens Serum Institut

Artillerivej 5

2300 Copenhagen

Denmark

gihc@ssi.dk

Conflict of interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declared no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Summary

Congenital heart defects (CHDs) are the most common congenital malformations and affect neonatal mortality and morbidity. The aetiology of CHDs is complex. Large cohort studies have reported an association between higher risk of CHDs in the offspring and individual maternal metabolic disorders such as obesity, diabetes, hypertension, and preeclampsia, all conditions that can be related to insulin resistance or hyperglycaemia and possibly metabolic syndrome (MetS). The aim of this review is to evaluate the existing evidence on the association between maternal metabolic disorders, defined as obesity, diabetes, hypertension, preeclampsia, dyslipidaemia, and MetS, or combinations thereof and CHDs overall as well as by subtype in the offspring. A literature search of PubMed and Embase databases identified 2,076 studies, 30 qualified for inclusion. All but one study investigated the individual metabolic disorders and their association with CHDs. Some disorders (obesity, gestational diabetes, and hypertension) increased risk of CHDs marginally whereas pre-gestational diabetes and early-onset preeclampsia were strongly associated with CHDs, without consistent differences between CHD subtypes. Future studies of the role of aberrations of the glucose-insulin homeostasis in the common aetiology and mechanisms of metabolic disorders, present during pregnancy, and their association with CHDs as well as subtypes of CHDs are needed.

Abbreviations:

CHDs, congenital heart defects; MetS, metabolic syndrome; PE, preeclampsia; BMI, body mass index; GDM, gestational diabetes; DM2, diabetes type 2; DM1, diabetes type 1; ICD-10, International Classification of Diseases, 10th revision; OR, odds ratio; RR, risk ratio; PR, prevalence ratio; CI, 95% confidence interval; PGDM, pre-gestational diabetes.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1. Introduction

Congenital heart defects (CHDs) are structural malformations of the heart and/or the great intrathoracic vessels. They are the most frequent congenital malformation[1] and prevalence is estimated to be around 8-10 per 1,000 live births worldwide.[1–4] The most critical and severe defects, the major CHDs, (1-2 per 1,000 live births) have a serious impact on neonatal mortality and morbidity, and frequently result in neonatal heart failure or circulatory collapse requiring acute surgery.[4] However, other types of CHDs, like bicuspid aortic valve and transient septal heart defects, are far more frequent but of limited clinical significance.

The aetiology of CHDs is complex and poorly understood. An identifiable underlying cause (genetic and/or environmental) is present in 20-30% of CHDs.[5] Thus, 8-10% of CHDs can be attributed to chromosomal aberrations (e.g., DiGeorge syndrome, Down syndrome, Turner syndrome, etc.)[5,6]; while 5-15% may be the result of single-nucleotide or pathogenic copy number variants.[5,7] Additionally, viral infections in pregnancy (e.g., rubella), as well as exposure to certain teratogenic substances (e.g., alcohol or antiepileptic drugs)[8] may cause CHDs if the foetus is exposed at a critical point in development.

The normal pregnancy is an adaptive interplay between the maternal metabolism and foetal development. Differentiation of cardiac tissues begins in the third week of gestation, and by week eight, the foetal heart has undergone major changes, and will resemble the postnatal heart in structure and function.[9] Thus, the maternal-foetal interaction in the first two months of pregnancy is likely to be the most relevant window in time for a causative relation between maternal metabolism and CHDs. In first trimester, the foetus does not have the ability to secrete insulin, which may result in foetal hyperglycaemia in the event of relative maternal insulin resistance.[10] Animal models have shown that in embryos of chicks and rodents, exogenous glucose may cause a variety of malformations.[11,12] The significance of foetal hyperglycaemia has not been demonstrated in humans, but increasingly worse glycaemic control around conception in women with diabetes type 1 (DM1) has recently been reported to be associated with a progressively increased risk of CHDs in the offspring.[13]

Large cohort studies from Scandinavia and North America have reported an association between increased risk of CHDs and maternal metabolic disorders such as obesity,[14,15] diabetes,[16–18] hypertension,[19,20] and preeclampsia (PE).[21,22]

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

All these metabolic disorders can be associated with hyperglycaemia and underlying insulin resistance, and thereby through the metabolic syndrome (MetS).[23,24]

MetS includes a cluster of metabolic disorders in combination, usually any three of the following: abdominal obesity, insulin resistance, hypertension, and dyslipidaemia.[23,25] It is commonly reported to be a risk factor for diabetes type 2 (DM2) and cardiovascular disease in a non-pregnant population. Only a single multi-centre study from Australia, New Zealand and United Kingdom has assessed MetS in pregnant women and reported an incidence of 12.3% at 15 weeks' gestation[26] using the International Diabetes Federation criteria.[25] It is plausible that obesity, diabetes, hypertension, PE and dyslipidaemia as individual conditions, or more likely in combination, during pregnancy are expressions of insulin resistance and MetS.[23,24] Combinations of several maternal metabolic disorders in the same pregnancy (defined as obesity, diabetes, hypertension, PE, and dyslipidaemia), all related to MetS, are likely to be associated with higher risk of CHDs in the offspring as compared to women with a single disorder.

The aim of this systematic review is to evaluate the literature of associations between maternal metabolic disorders (obesity, diabetes, hypertension, PE, dyslipidaemia, or MetS) or combinations thereof and CHDs in the offspring. The relation with overall occurrence of CHDs as well as CHDs broken down into individual subtypes. Since these maternal metabolic disorders likely persist over time, they may be relevant for the risk of CHDs in subsequent pregnancies. On this background, we will point to gaps in current knowledge and make recommendations for future research possibly paving the way to improved prevention of CHDs.

2. Methods

2.1 Search strategy

A systematic literature search of papers published between January 1, 1990 and October 6, 2019 was conducted using PubMed and Embase. MetS was initially described by G.M. Reaven in 1988 as an "insulin resistance syndrome",[27] and the literature search was limited to publications focussing on its role in CHDs. The search strategy used keywords that combined CHDs and pregnancies with maternal metabolic disorders (obesity, diabetes, hypertension, PE, dyslipidaemia and/or MetS). Although DM1 is not a part of the MetS, it was included in the review as a metabolic

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

disorder because the associated hyperglycaemia is known to be associated with CHDs. More details about the literature search can be found in Table S1. Subsequently, reference lists from the individual papers were reviewed for additional relevant studies.

2.2 Exposures, outcomes and definitions

The exposures of interest were maternal overweight and obesity, diabetes (DM1, DM2 or gestational diabetes (GDM)), hypertension, PE, dyslipidaemia, and/or MetS during pregnancy. Maternal body mass index (BMI) (weight in kilograms divided by the square of the height in meters (kg/m^2)) was defined as pre-pregnancy or early-pregnancy BMI measured in first trimester. The outcome of interest was CHDs defined as structural malformations of the heart chambers, heart valves, great arteries and septal defects, corresponding to DQ20-26 in the World Health Organization International Classification of Diseases (ICD-10) or diagnoses referable to these. The CHD diagnoses are described as "any CHDs" for the whole group of heart defects (only including studies that explicitly listed their definition thereof), "major CHDs" for a group of the most critical and severe CHD diagnoses or as CHD subtypes in relation to the maternal disorders. Studies could include both singleton and multiple births.

2.3 Eligibility criteria

Two different authors (GH, PLH and/or INT) screened all titles and abstracts individually. Studies were initially eligible if they met the following criteria: 1. Studies were published in English; 2. Studies were case-control or cohort studies; 3. The exposures of interest were maternal overweight or obesity, hypertension, PE, diabetes, dyslipidaemia, and/or MetS; and 4. The outcome of interest was CHDs in the offspring.

2.4 Quality assessment

One author (GH) conducted the study selection and quality assessment based on a full-text review. Any doubts were resolved by discussion with at least one co-author. The Newcastle-Ottawa Scale was used to assess the quality of

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

eligible studies.[28] Using this tool (Table S2), each study was judged on three categories: 1. selection of cohorts or cases and controls; 2. comparability of cohorts or cases and controls on the basis of the design or analysis; and 3. ascertainment of outcome or exposure. Highest quality studies could be awarded nine stars. If a study received seven or more stars (Table S3), it was considered of high methodological quality and included in the review.[28]

Data was extracted to figures without processing results. Results are presented as odds ratios (OR), risk ratios (RR) or prevalence ratios (PR) with 95% confidence interval (CI). Results are presented adjusted (aOR/aRR/aPR) for pertinent possible confounding factors, if accessible.

3. Results

3.1 Study identification and selection

The selection of studies is described in Figure 1. In the event of multiple publications using the same data, we included the study that provided the most comprehensive information. A total of 30 publications were included in the review (Table 1 and Table S3). Among these, 15 dealt with maternal overweight or obesity,[14,15,19,29–40] nine dealt with pre-gestational diabetes (PGDM),[16–18,40–45] four dealt with DM1,[13,19,46,47] two dealt with DM2,[19,46] seven dealt with GDM,[16–18,39,40,44,47] four dealt with hypertension,[19,20,41,46] three dealt with PE,[21,22,48] and none were about dyslipidaemia or MetS (as a diagnostic category). Except for the combination of PGDM and GDM, five studies investigated more than one maternal metabolic disorder (but not in combination),[19,39–41,46] and one study assessed a combination of two conditions (obesity and GDM) and the risk of CHDs.[31]

3.2 Study characteristics

The 30 included studies consisted of 17 cohort studies and 13 case-control studies. Characteristics of the 30 studies are presented in Table 1 and Table S3. Two examined populations of non-European descent (Taiwan and China).[39,46] Half of the studies reported results from livebirths only; eight studies had populations including both singleton and multiple births; and nine studies did not state whether they included only singleton or multiple births. Associations

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

between maternal metabolic disorders and CHDs are illustrated in Figure 2 (any CHDs) and Figures S1-S20 (CHD subtypes). All 30 studies were assessed using the Newcastle-Ottawa Scale and were required to be of high methodological quality (Table S2 and Table S3). Study designs were heterogeneous, particularly regarding the definition and categorization of the maternal metabolic disorders.

3.3 Maternal overweight or obesity and CHDs in the offspring

Several studies have investigated the association between maternal overweight or obesity and any CHDs.[14,15,19,31,33,37,49] In Figure 2, four out of seven studies found a significant association between maternal obesity (BMI ≥ 30 kg/m^2) and any CHDs. Three of them reported higher risk estimates for any CHDs with higher maternal BMI: RR 1.07 (BMI 25-29.9 kg/m^2) and RR 1.60 (BMI ≥ 40 kg/m^2);[14] aOR 1.15 (BMI 25-29.9 kg/m^2) and aOR 1.34 (BMI ≥ 40 kg/m^2);[15] and aOR 1.16 (BMI 25-29.9 kg/m^2) and aOR 1.31 (BMI ≥ 35 kg/m^2).[31] The fourth study only reported an association between maternal obesity diagnosed as ICD-10 codes and any CHDs, and did not assess the risk in relation to BMI categories.[19] Three studies found no significant association between any CHDs in the offspring and maternal overweight or obesity.[33,37,49]

Most studies investigated specific CHD subtypes in relation to maternal BMI, these results are presented for maternal obesity (BMI ≥ 30 kg/m^2) in Figures S1-S20. Some studies found significant associations between obesity and 13 CHD subtypes, however, other studies did not find a significant association.

3.4 Maternal pre-gestational diabetes and CHDs in the offspring

Most studies defined PGDM as either DM1 or DM2 (Table S3). Only four studies assessed DM1 or DM2 individually.[13,19,46,47] Seven studies found a strong significant association with any CHDs (Figure 2), irrespective of the type of diabetes investigated, PGDM,[16–18,44] DM1,[13,19,46] or DM2.[19,46]

Two studies presented associations between PGDM and major CHDs, but they defined major CHDs differently: Leirgul et al. found an association between PGDM and major CHDs (aRR 3.34, CI 2.48-4.49),[18] and Chou et al. found an

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

association between DM2 and major CHDs (aOR 2.80, CI 2.04-3.85), but did not find a significant association between DM1 and major CHDs (aOR 0.73, 0.10–5.32).[46]

Several studies have investigated the relationship between PGDM, DM1 or DM2 and specific CHD diagnoses[16–19,40–45,47] and in many cases found a strong significant association (Figures S1-S20).

3.5 Maternal gestational diabetes and CHDs in the offspring

Five studies reported an association between GDM and any CHDs,[16–18,39,44] but only the results from four of them are shown in Figure 2. The last study by Øyen et al. found an association between any CHDs and GDM diagnosed in the third trimester (aRR 1.36; CI 1.07-1.69), but did not find a significant association between any CHDs and GDM diagnosed in the second trimester.[16] Five studies reported a weak association between GDM and some subtypes of CHDs (Figures S1-S20).

3.6 Maternal chronic hypertension and CHDs in the offspring

Two large cohort studies from Canada and Taiwan reported a significant association between maternal pre-existing chronic hypertension and any CHDs (Figure 2).[19,46] Two studies assessed the association between subtypes of CHDs and chronic hypertension,[19,41] (Figures S1-S20), but associations were inconsistent. None of the three studies mentioned reported on potential antihypertensive drug use by the mothers. An American case-control study with 10,625 cases with CHDs found a significant association between untreated hypertension and any CHDs (Figure 2) as well as for five subtypes of CHDs (Figures S1-S20).[20]

3.7 Maternal preeclampsia or gestational hypertension and CHDs in the offspring

Three studies investigated associations between PE and any CHDs or major CHDs. Although the definition of PE varied among the studies, all studies defined early-onset PE as diagnosed before gestational week 34, and the association

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

with any CHDs can be seen in Figure 2. Pregnancies with PE were associated with any CHDs (PR 1.57, CI 1.48-1.67),[22] and early-onset PE was associated with major CHDs (aRR 2.7, CI 1.3-5.6,[48] and aPR 3.64, CI 2.17-6.10[22]), all compared to normotensive pregnancies.

Weaker associations, between PE and any CHDs, were reported when PE was diagnosed later in pregnancy: PE with delivery at 34 to 36 weeks (OR 2.82, CI 2.38-3.34);[21] PE at term (OR 1.16, CI 1.06-1.27);[21] and late-onset PE (> 34 weeks' gestation) (aPR 1.14, CI 1.06-1.23).[22] Furthermore, Boyd et al. did not find an association between gestational hypertension and any CHDs.[21] The studies also assessed subtypes of CHDs and their association with early-onset PE, which are illustrated in Figures S1-S20, especially atrioventricular septal defects (Figure S9) and atrial septal defects (Figure S19) were strongly associated with early-onset PE.

3.8 Risk of CHDs in the offspring in subsequent pregnancies

Two studies assessed PE and CHDs, and potential risks of both in subsequent pregnancies.[21,48] While, Brodwall et al. did not find an association between PE and CHDs across pregnancies,[48] Boyd et al. reported a much higher risk of having a child with CHDs in subsequent pregnancies after a pregnancy with PE and delivery before 34 weeks' gestation (OR 7.91, CI 6.06-10.3). Boyd et al. also found an association between a previous pregnancy with a child with CHDs and increased risk of PE with delivery before 34 weeks' gestation in subsequent pregnancies (OR 2.37; CI 1.68-3.34).[21] Studies on the other maternal metabolic disorders did not comprise an analysis of risks in subsequent pregnancies.

3.9 Combination of maternal obesity and gestational diabetes and CHDs in the offspring

Only one study comprised an assessment of the risk associated with pregnancies affected by two maternal metabolic conditions. Gilboa et al. reported a possible additive effect of the combination of maternal obesity (BMI ≥ 30 kg/m^2) and GDM and the risk of any CHDs compared to only obesity (aOR 1.82 vs. 1.31).[31] The relation between the combination of maternal obesity and GDM and subtypes of CHDs are reported in Figures S1-S20 showing a significant association for six subtypes of CHDs.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

4. Discussion

4.1 Main findings

The associations between any CHDs and maternal metabolic disorders fall in three groups: A. chronic hypertension, GDM, and obesity with OR/RR/PR of 1.2-1.9; B. PGDM with OR/RR/PR around 3-4; and C. early-onset PE with OR/RR/PR of 5-7. Thus, for the most prevalent maternal conditions, the associated risks of CHDs are only marginally elevated. Although maternal obesity is associated with higher risk of GDM, DM2, hypertension, PE, and dyslipidaemia,[50] no studies assessing the association between CHDs in the offspring and the combination of all maternal metabolic disorders were identified, and only one study dealt with the combination of two maternal metabolic conditions (obesity and GDM) as risk factor for CHDs in the offspring.[31] All other studies investigated the individual metabolic disorders and their association with CHDs, and there were no eligible studies on dyslipidaemia. Overall, those studies found a significant association between any CHDs and obesity, PGDM, GDM, hypertension, or early-onset PE, respectively (Figure 2). Contradictory evidence of associations with subtypes of CHDs were noted for most maternal conditions, with the exception of early-onset PE, which was strongly associated with both atrioventricular septal defects (Figure S9) and atrial septal defects (Figure S19); and PGDM which was strongly associated with most subtypes (Figures S1-S20).

Early-onset PE was strongly associated with a higher risk of having a child with CHD in subsequent pregnancies, studies on the other maternal metabolic disorders did not approach risks in subsequent pregnancies.

4.2 Aetiological considerations and possible prevention of CHDs

4.2.1 Relation between maternal metabolic disorders and foetal heart development

There is a clear pathophysiological connection between maternal insulin resistance and foetal CHDs, with glucose-mediated mechanisms of CHD involving multiple developmental pathways:[51] comprise left-right patterning,[52] alterations in neural crest cells migration and formation,[53,54] increased apoptosis[55,56] as well as changes in nitric oxide signalling,[57] and impaired autophagy.[58] All these mechanisms may cause or modify the development of CHDs. The investigated maternal metabolic disorders (obesity, diabetes, hypertension, preeclampsia, dyslipidaemia, and MetS)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

are all linked to insulin resistance and/or hyperglycaemia.[24,59] The finding of the same association for these conditions as for DM1[16] justifies a particular focus on the role of aberrations in the glucose-insulin homeostasis. Obesity, DM1, DM2, chronic hypertension, and dyslipidaemia are present prior to conception and therefore affect maternal metabolism and foetal development during the essential first two months of pregnancy. However, PE and GDM are per definition not diagnosed before mid-pregnancy,[60,61] but it is likely that subclinical metabolic alterations emerge at a much earlier stage. It can be challenging to distinguish GDM from PGDM since most women are not screened for diabetes before pregnancy, and up to 50% of women diagnosed with GDM develop DM2 within five years after giving birth.[62] So it is plausible that many women with GDM might already be insulin resistant without it being detectable in first trimester. This is particularly challenging because fasting and postprandial glucose concentrations are normally lower in the early part of pregnancy (e.g., first trimester and first half of second trimester) than in normal, non–pregnant women.[61] Insulin resistance is more pronounced early in pregnancies with PE compared to pregnancies without PE.[24,63] In first trimester pregnancies that later develop PE are characterised by changes in IGF-axis markers, e.g. PAPP-A, and ProMBP,[64,65] placental proteins,[66] and adipokines, e.g. leptin and adiponectin,[67,68] indicating that the clinical presentation of PE is preceded by a foeto-maternal dyscrine condition. The fact that the nutritional status of the foetus influences the risk of cardiovascular disease in adulthood (Barker Hypothesis)[69] - also indicates that placental function may play a role in the aetiology of foetal malformations. There is a need to identify particular pathways where perturbations, especially in the glucose-insulin axis, cause specific malformations, but such studies will have to be large as some of the malformations are fairly rare and the molecular aetiology likely heterogeneous.

4.2.2 Possible teratogenic effect of medication

Women with chronic hypertension or DM1 will most likely be undergoing medical treatment as well as some women with DM2 will be treated with antidiabetic drugs. Some of these drugs might have a teratogenic effect and by not taking them into considerations in the studies, they could influence the estimates of association. It is thus important to distinguish between the effects of the drugs and the conditions proper. Insulin is not believed to be teratogenic,[70] suggesting that the focus should be on the insulin resistance and the glucose levels. Observational studies suggest that exposure to either metformin or beta-blockers during pregnancy may actually increase the risk of certain types of

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CHDs in the foetus.[20,71] A meta-analysis by Ramakrishnan et al. observed an association between untreated hypertension and CHDs, which suggests that the association between hypertension and CHDs is not simply due to teratogenic effects of medication alone, but the effect was larger for treated hypertension.[72] Thus, antihypertensive medications may lead to an additional increase in risk, but it might also just indicate a more severe disease in the mother.

4.2.3 Prevention of CHDs in the offspring

It is very well-established that maternal obesity is associated with marginally increased risk of CHDs, and two meta-analyses reported a dose-response effect on risk of CHDs with increasing BMI.[73,74] But an increase of 20-40% of a very small risk in general may not be clinically significant. Particularly as it has not yet been shown that weight reduction normalizes the risk and a study showing such an effect would be complicated and difficult to perform. Future studies investigating the prevalence of CHDs in obese pregnant women could compare women who had undergone bariatric surgery with a control group as well as risk in pregnancies before and after the surgery as it has been done in studies on birth weight and obesity in childhood.[75,76] The Swedish cohort study of 1.2 million pregnant women with DM1 showed that poor glycaemic control around conception was associated with a progressively higher risk of CHDs in the offspring.[13] PGDM and early-onset PE have a strong association with CHDs, however, the clinical significance of preventive measures has not been established.

4.3 Heterogeneity in studies

Comparison of results from different studies in this review was hampered by heterogeneity. This is due to several factors: 1. Case-control studies provide estimates of risk that may be less valid and reliable than prospective, population-based cohort studies for estimating occurrence of CHDs– i.e., for some subtypes of CHDs, the cohort studies find a significant association while the results from the case-control studies are insignificant. 2. The studies assessing maternal obesity and CHDs often excluded pregnancies with PGDM, whereas others did not and are therefore difficult to compare; studies on obesity usually also divided maternal BMI into categories that distinguished

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

them from a direct comparison with another study. 3. Diagnostic criteria for PGDM and GDM were not always explained. 4. Not all studies include stillbirths and terminated pregnancies, which could skew the results, i.e., the risk of CHDs in live born offspring of women with obesity relative to women without obesity might be overestimated, since it is well-known that congenital malformations are more difficult to detect by prenatal ultrasound in these women and they are therefore not necessarily given the possibility to terminate the pregnancy in case of a severe malformation.[77] 5. Studies on both singleton and multiple births without distinguishing between them may add to the heterogeneity because the risk of CHDs is higher in multiple birth.[78]

We presented adjusted risks and compared them although the studies did not all adjust for the same confounders. Many studies adjust for maternal age, parity and year of birth, while others also adjust for race/ethnicity, education, smoking, marital status etc. Even though not always available, we could have presented crude risks, however, we believe that the adjusted risks represent the best possible estimate since results otherwise would have been known to be biased.

4.6 Significance of genetic aetiology

The aetiology of CHD is complex and the important breakthroughs in next generation sequencing of whole genomes as well as implementation of chromosomal micro arrays have as of now led to the identification of a strong genetic component in 15-20% of CHD cases.[5] The genetic aetiology ranges from chromosomal disorders over micro-deletions to copy number variants and single-gene disorders. Many of the genetic causes of CHDs are characterized by extensive phenotypic variability and a broad spectrum of comorbidities.[5] Thus, some cases of e.g. Williams syndrome[79] as well as Bardet-Biedl syndrome[80] exhibit malformations in combinations with obesity, DM2, and hypertension. In cases where the mother carries genetic variants that cause or pre-dispose to such conditions, the association between CHDs and maternal metabolic disorders might be one of common aetiology (horizontal pleiotropy) rather than one of a causal relation between maternal conditions and the development of CHDs (vertical pleiotropy). With further advances in genetic characterization of CHDs, one might see a more detailed understanding of the extent of comorbidities in CHD-associated genetic disorders. This phenomenon might bias the association analysis.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

4.7 Strengths and limitations

The strength of this review is that we have selected only high-quality, original research studies from a systematic literature search. However, we have limited our selection of studies to those published in English and from 1990 and after, which may have excluded a number of high-quality studies, which were published in another language or before 1990. However, the screening of the references of the articles included did not reveal relevant studies published before 1990. Furthermore, our review did not include meta-analyses as prescribed by PRISMA since we found the data too heterogeneous to summarize in a meta-analysis.

4.8 Perspectives

The global prevalence of CHDs has increased by 10% every five years between 1970 and 2017, which probably is due to increased detection of milder lesions.[2] The incidence of MetS often parallels the incidence of obesity, which has nearly tripled worldwide since 1975,[81] and Centers for Disease Control and Prevention estimated that 40% of women aged 20-39 years old in the United States had a BMI ≥ 30 kg/m^2 in 2017-2018.[82] Maternal obesity and dyslipidaemia increases the risk of developing both PE and GDM,[83,84] GDM closely associated with risk of DM2, PE increases the risk of future chronic hypertension,[85] and studies indicate that women with PE have increased risk of insulin resistance later in life.[86] So, the maternal metabolic disorders might be related to later MetS (except for DM1), and all components are associated with CHDs in offspring – either individually or with an additive effect. Our analysis shows that there is a remarkable lack of knowledge on several aspects of the link between maternal metabolic disorders and CHDs in the offspring. Large population-based studies are needed to identify possible synergistic effects. Indeed, the combination may have a greater impact than each individual factor and result in amplified risk of CHDs – also taking into consideration at what time the maternal metabolic disorder develops in relationship to the development of the foetal heart. Furthermore, such studies should be ethnically inclusive, and also include women of different socio-economic status. There is also a need for more detailed studies of the molecular mechanisms of CHDs, especially regarding the possibly common underlying pathophysiological mechanisms, insulin resistance and glucose-insulin homeostasis in particular, and their genomic basis. A combination of such studies in carefully investigated cohorts and the use of electronic health records in a population-wide biobank setting could bring relevant knowledge on

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

mechanisms that might pave the way to preventive approaches to CHDs. Furthermore, it is important to examine whether a modification of a pre-existing condition influences risks for CHDs.

5. Conclusion

CHDs are the most common malformations and a major cause of morbidity and mortality in childhood. Although the aetiology is complex, it is important to identify risk factors in order to pave the way for targeted prevention of CHDs. Our review shows that there is a well-established association, albeit to a varying extent, between individual maternal metabolic disorders such as obesity, diabetes, hypertension, and PE with increased risk of CHDs in the child. Since occurrence of MetS is rapidly increasing, there is a need for such studies. Secondly, there is a need for large studies based on genetically characterized CHD cases, where the association with MetS could be an expression of comorbidity involving both CHDs and maternal metabolic disorders implying aberrations of the glucose-insulin homeostasis. Thirdly, there is a need for studies covering populations other than those of European and Asian descent, particularly as the prevalence of MetS and its different manifestations vary widely around the globe. Such studies may result in the identification of subgroups of women, in whom MetS might be of particularly importance as a risk factor. Finally, it is important to examine whether preventive actions against pre-pregnancy maternal metabolic disorders influences the risk of CHDs.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Dolk H, Loane M, Garne E, European Surveillance of Congenital Anomalies (EUROCAT) Working Group. Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. *Circulation*. 2011;123(8):841-849.

2. Liu Y, Chen S, Zühlke L, et al. Global birth prevalence of congenital heart defects 1970–2017: updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol*. 2019;48(2):455-463.

3. van der Linde D, Konings EEM, Slager MA, et al. Birth Prevalence of Congenital Heart Disease Worldwide. *J Am Coll Cardiol*. 2011;58(21):2241-2247.

4. Lytzen R, Vejlstrup N, Bjerre J, et al. Live-Born Major Congenital Heart Disease in Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013. *JAMA Cardiol*. 2018;3(9):829-837.

5. Pierpont ME, Brueckner M, Chung WK, et al. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. *Circulation*. 2018;138(21):e653-e711.

6. van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJM. The changing epidemiology of congenital heart disease. *Nat Rev Cardiol*. 2011;8(1):50-60.

7. Jin SC, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. *Nat Genet*. 2017;49(11):1593-1601.

8. Hoffman JIE. Epidemiology of congenital heart disease: etiology, pathogenesis, and incidence. In: Yagel S, Silverman NH, Gembruch U, eds. *Fetal Cardiology: Embryology, Genetics, Physiology, Echocardiographic Evaluation, Diagnosis and Perinatal Management of Cardiac Diseases*. 2nd ed. Taylor & Francis; 2009: 101-110.

9. Wenink ACG. Cardiovascular development. In: Yagel S, Silverman NH, Gembruch U, eds. *Fetal Cardiology: Embryology, Genetics, Physiology, Echocardiographic Evaluation, Diagnosis and Perinatal Management of Cardiac Diseases*. 2nd ed. Taylor & Francis; 2009:1-8.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

10. Rorsman P, Arkhammar P, Bokvist K, et al. Failure of glucose to elicit a normal secretory response in fetal pancreatic beta cells results from glucose insensitivity of the ATP-regulated K+ channels. *Proc Natl Acad Sci U S A*. 1989;86(12):4505-4509.

11. Hughes AF, Freeman RB, Fadem T. The teratogenic effects of sugars on the chick embryo. *J Embryol Exp Morphol*. 1974;32(3):661-674.

12. Garnham EA, Beck F, Clarke CA, Stanisstreet M. Effects of glucose on rat embryos in culture. *Diabetologia*. 1983;25(3):291-295.

13. Ludvigsson JF, Neovius M, Söderling J, et al. Periconception glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study in Sweden. *BMJ*. 2018;362:k2638.

14. Persson M, Razaz N, Edstedt Bonamy A-K, Villamor E, Cnattingius S. Maternal Overweight and Obesity and Risk of Congenital Heart Defects. *J Am Coll Cardiol*. 2019;73(1):44-53.

15. Brite J, Laughon SK, Troendle J, Mills J. Maternal overweight and obesity and risk of congenital heart defects in offspring. *Int J Obes 2005*. 2014;38(6):878-882.

16. Øyen N, Diaz LJ, Leirgul E, et al. Prepregnancy Diabetes and Offspring Risk of Congenital Heart Disease: A Nationwide Cohort Study. *Circulation*. 2016;133(23):2243-2253.

17. Hoang TT, Marengo LK, Mitchell LE, Canfield MA, Agopian AJ. Original Findings and Updated Meta-Analysis for the Association Between Maternal Diabetes and Risk for Congenital Heart Disease Phenotypes. *Am J Epidemiol*. 2017;186(1):118-128.

18. Leirgul E, Brodwall K, Greve G, et al. Maternal Diabetes, Birth Weight, and Neonatal Risk of Congenital Heart Defects in Norway, 1994-2009. *Obstet Gynecol*. 2016;128(5):1116-1125.

19. Liu S, Joseph KS, Lisonkova S, et al. Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. *Circulation*. 2013;128(6):583-589.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

20. Fisher SC, Van Zutphen AR, Werler MM, et al. Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. *Hypertens Dallas Tex 1979*. 2017;69(5):798-805.

21. Boyd HA, Basit S, Behrens I, et al. Association Between Fetal Congenital Heart Defects and Maternal Risk of Hypertensive Disorders of Pregnancy in the Same Pregnancy and Across Pregnancies. *Circulation*. 2017;136(1):39-48.

22. Auger N, Fraser WD, Healy-Profitós J, Arbour L. Association Between Preeclampsia and Congenital Heart Defects. *JAMA*. 2015;314(15):1588-1598.

23. Cornier M-A, Dabelea D, Hernandez TL, et al. The metabolic syndrome. *Endocr Rev*. 2008;29(7):777-822.

24. Jeyabalan A, Hubel CA, Roberts JM. Metabolic Syndrome and Preeclampsia. In: Taylor RN, Roberts JM, Cunningham FG, Lindheimer MD, eds. *Chesley's Hypertensive Disorders in Pregnancy*. 4th ed. Academic Press; 2015:133-160.

25. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. *Obes Rev Off J Int Assoc Study Obes*. 2015;16(1):1-12.

26. Grieger JA, Bianco-Miotto T, Grzeskowiak LE, et al. Metabolic syndrome in pregnancy and risk for adverse pregnancy outcomes: A prospective cohort of nulliparous women. *PLoS Med*. 2018;15(12):e1002710.

27. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes*. 1988;37(12):1595-1607.

28. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December 18, 2019.

29. Block SR, Watkins SM, Salemi JL, et al. Maternal pre-pregnancy body mass index and risk of selected birth defects: evidence of a dose-response relationship. *Paediatr Perinat Epidemiol*. 2013;27(6):521-531.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

30. Blomberg MI, Källén B. Maternal obesity and morbid obesity: the risk for birth defects in the offspring. *Birt Defects Res A Clin Mol Teratol*. 2010;88(1):35-40.

31. Gilboa SM, Correa A, Botto LD, et al. Association between prepregnancy body mass index and congenital heart defects. *Am J Obstet Gynecol*. 2010;202(1):51.e1-51.e10.

32. Mills JL, Troendle J, Conley MR, Carter T, Druschel CM. Maternal obesity and congenital heart defects: a population-based study. *Am J Clin Nutr*. 2010;91(6):1543-1549.

33. Rankin J, Tennant PWG, Stothard KJ, Bythell M, Summerbell CD, Bell R. Maternal body mass index and congenital anomaly risk: a cohort study. *Int J Obes 2005*. 2010;34(9):1371-1380.

34. Shaw GM, Carmichael SL. Prepregnant obesity and risks of selected birth defects in offspring. *Epidemiol Camb Mass*. 2008;19(4):616-620.

35. Cedergren MI, Källén BAJ. Maternal obesity and infant heart defects. *Obes Res*. 2003;11(9):1065-1071.

36. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal Obesity and Risk for Birth Defects. *Pediatrics*. 2003;111(Supplement 1):1152-1158.

37. Watkins ML, Botto LD. Maternal prepregnancy weight and congenital heart defects in offspring. *Epidemiol Camb Mass*. 2001;12(4):439-446.

38. Shaw GM, Todoroff K, Schaffer DM, Selvin S. Maternal height and prepregnancy body mass index as risk factors for selected congenital anomalies. *Paediatr Perinat Epidemiol*. 2000;14(3):234-239.

39. Liu X, Liu G, Wang P, et al. Prevalence of congenital heart disease and its related risk indicators among 90,796 Chinese infants aged less than 6 months in Tianjin. *Int J Epidemiol*. 2015;44(3):884-893.

40. Agopian AJ, Moulik M, Gupta-Malhotra M, Marengo LK, Mitchell LE. Descriptive epidemiology of non-syndromic complete atrioventricular canal defects. *Paediatr Perinat Epidemiol*. 2012;26(6):515-524.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

41. Vereczkey A, Gerencsér B, Czeizel AE, Szabó I. Association of certain chronic maternal diseases with the risk of specific congenital heart defects: a population-based study. *Eur J Obstet Gynecol Reprod Biol*. 2014;182:1-6.

42. Kovalenko AA, Anda EE, Odland JØ, Nieboer E, Brenn T, Krettek A. Risk Factors for Ventricular Septal Defects in Murmansk County, Russia: A Registry-Based Study. *Int J Environ Res Public Health*. 2018;15(7):1320.

43. Vinceti M, Malagoli C, Rothman KJ, et al. Risk of birth defects associated with maternal pregestational diabetes. *Eur J Epidemiol*. 2014;29(6):411-418.

44. Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. *Am J Obstet Gynecol*. 2008;199(3):237.e1-9.

45. Erickson JD. Risk factors for birth defects: data from the Atlanta Birth Defects Case-Control Study. *Teratology*. 1991;43(1):41-51.

46. Chou H-H, Chiou M-J, Liang F-W, Chen L-H, Lu T-H, Li C-Y. Association of maternal chronic disease with risk of congenital heart disease in offspring. *CMAJ Can Med Assoc J J Assoc Medicale Can*. 2016;188(17-18):E438-E446.

47. Sharpe PB, Chan A, Haan EA, Hiller JE. Maternal diabetes and congenital anomalies in South Australia 1986-2000: a population-based cohort study. *Birt Defects Res A Clin Mol Teratol*. 2005;73(9):605-611.

48. Brodwall K, Leirgul E, Greve G, et al. Possible Common Aetiology behind Maternal Preeclampsia and Congenital Heart Defects in the Child: a Cardiovascular Diseases in Norway Project Study. *Paediatr Perinat Epidemiol*. 2016;30(1):76-85.

49. Liu S, Rouleau J, León JA, Sauve R, Joseph KS, Ray JG. Impact of pre-pregnancy diabetes mellitus on congenital anomalies, Canada, 2002-2012. *Health Promot Chronic Dis Prev Can Res Policy Pract*. 2015;35(5):79-84.

50. Denison FC, Aedla NR, Keag O, et al. Care of Women with Obesity in Pregnancy: Green-top Guideline No. 72. *BJOG Int J Obstet Gynaecol*. 2019;126(3):e62-e106.

51. Helle E, Priest JR. Maternal Obesity and Diabetes Mellitus as Risk Factors for Congenital Heart Disease in the Offspring. *J Am Heart Assoc*. 2020;9(8):e011541.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

52. Basu M, Zhu J-Y, LaHaye S, et al. Epigenetic mechanisms underlying maternal diabetes-associated risk of congenital heart disease. *JCI Insight*. 2017;2(20):e95085.

53. Suzuki N, Svensson K, Eriksson UJ. High glucose concentration inhibits migration of rat cranial neural crest cells in vitro. *Diabetologia*. 1996;39(4):401-411.

54. Wang X-Y, Li S, Wang G, et al. High glucose environment inhibits cranial neural crest survival by activating excessive autophagy in the chick embryo. *Sci Rep*. 2015;5:18321.

55. Kumar SD, Vijaya M, Samy RP, et al. Zinc supplementation prevents cardiomyocyte apoptosis and congenital heart defects in embryos of diabetic mice. *Free Radic Biol Med*. 2012;53(8):1595-1606.

56. Wang F, Fisher SA, Zhong J, Wu Y, Yang P. Superoxide Dismutase 1 In Vivo Ameliorates Maternal Diabetes Mellitus-Induced Apoptosis and Heart Defects Through Restoration of Impaired Wnt Signaling. *Circ Cardiovasc Genet*. 2015;8(5):665-676.

57. Engineer A, Saiyin T, Lu X, et al. Sapropterin Treatment Prevents Congenital Heart Defects Induced by Pregestational Diabetes Mellitus in Mice. *J Am Heart Assoc*. 2018;7(21):e009624.

58. Wang G, Huang W, Cui S, et al. Autophagy is involved in high glucose-induced heart tube malformation. *Cell Cycle Georget Tex*. 2015;14(5):772-783.

59. Reaven GM. Insulin resistance: from bit player to centre stage. *CMAJ Can Med Assoc J J Assoc Medicale Can*. 2011;183(5):536-537.

60. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. *Lancet Lond Engl*. 2016;387(10022):999-1011.

61. WHO. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Available from: https://www.who.int/diabetes/publications/Hyperglycaemia_In_Pregnancy/en/. Accessed July 28, 2020.

62. National Institute for Health and Care Excellence. 2018 Surveillance of Diabetes in Pregnancy: Management from Preconception to the Postnatal Period (NICE Guideline NG3). Available from:

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

https://www.nice.org.uk/guidance/ng3. Published February 25, 2015. Updated August 26, 2015. Accessed May 3, 2020.

63. von Versen-Hoeynck FM, Powers RW. Maternal-fetal metabolism in normal pregnancy and preeclampsia. *Front Biosci J Virtual Libr*. 2007;12:2457-2470.

64. Pihl K, Larsen T, Krebs L, Christiansen M. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses. *Prenat Diagn*. 2008;28(12):1131-1135.

65. Pihl K, Larsen T, Laursen I, Krebs L, Christiansen M. First trimester maternal serum pregnancy-specific beta-1-glycoprotein (SP1) as a marker of adverse pregnancy outcome. *Prenat Diagn*. 2009;29(13):1256-1261.

66. De Villiers CP, Hedley PL, Placing S, et al. Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia. *Clin Chem Lab Med*. 2017;56(1):65-74.

67. Thagaard IN, Krebs L, Holm J-C, Lange T, Larsen T, Christiansen M. Adiponectin and leptin as first trimester markers for gestational diabetes mellitus: a cohort study. *Clin Chem Lab Med*. 2017;55(11):1805-1812.

68. Hedley PL, Placing S, Wøjdemann K, et al. Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia. *Prenat Diagn*. 2010;30(2):103-109.

69. Godfrey KM, Barker DJ. Fetal programming and adult health. *Public Health Nutr*. 2001;4(2B):611-624.

70. de Jong J, Garne E, Wender-Ozegowska E, Morgan M, de Jong-van den Berg LTW, Wang H. Insulin analogues in pregnancy and specific congenital anomalies: a literature review. *Diabetes Metab Res Rev*. 2016;32(4):366-375.

71. Given JE, Loane M, Garne E, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. *BMJ*. 2018;361:k2477.

72. Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis. *Pediatr Cardiol*. 2015;36(7):1442-1451.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

73. Zheng Z, Yang T, Chen L, et al. Increased maternal Body Mass Index is associated with congenital heart defects: An updated meta-analysis of observational studies. *Int J Cardiol*. 2018;273:112-120.

74. Liu X, Ding G, Yang W, et al. Maternal Body Mass Index and Risk of Congenital Heart Defects in Infants: A Dose-Response Meta-Analysis. *BioMed Res Int*. 2019;2019:1315796.

75. Berglind D, Willmer M, Näslund E, Tynelius P, Sørensen TIA, Rasmussen F. Differences in gestational weight gain between pregnancies before and after maternal bariatric surgery correlate with differences in birth weight but not with scores on the body mass index in early childhood. *Pediatr Obes*. 2014;9(6):427-434.

76. Willmer M, Berglind D, Sørensen TIA, Näslund E, Tynelius P, Rasmussen F. Surgically induced interpregnancy weight loss and prevalence of overweight and obesity in offspring. *PloS One*. 2013;8(12):e82247.

77. Best KE, Tennant PWG, Bell R, Rankin J. Impact of maternal body mass index on the antenatal detection of congenital anomalies. *BJOG Int J Obstet Gynaecol*. 2012;119(12):1503-1511.

78. Herskind AM, Almind Pedersen D, Christensen K. Increased prevalence of congenital heart defects in monozygotic and dizygotic twins. *Circulation*. 2013;128(11):1182-1188.

79. Pober BR. Williams-Beuren syndrome. *N Engl J Med*. 2010;362(3):239-252.

80. Forsythe E, Beales PL. Bardet-Biedl syndrome. *Eur J Hum Genet EJHG*. 2013;21(1):8-13.

81. WHO. Obesity and overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Published April 1, 2020. Accessed May 3, 2020.

82. Centers for Disease Control and Prevention. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018. Available from: https://www.cdc.gov/nchs/products/databriefs/db360.htm. Published February 2020. Accessed June 24, 2020.

83. Poston L, Caleyachetty R, Cnattingius S, et al. Preconceptional and maternal obesity: epidemiology and health consequences. *Lancet Diabetes Endocrinol*. 2016;4(12):1025-1036.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

84. Baumfeld Y, Novack L, Wiznitzer A, et al. Pre-Conception Dyslipidemia Is Associated with Development of Preeclampsia and Gestational Diabetes Mellitus. *PloS One*. 2015;10(10):e0139164.

85. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007;335(7627):974.

86. Alonso-Ventura V, Li Y, Pasupuleti V, Roman YM, Hernandez AV, Pérez-López FR. Effects of preeclampsia and eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis. *Metabolism*. 2020;102:154012.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table and Figure Legends

FIGURE 1. Flow diagram

The process of selection of studies that were included in the review. Literature search included studies published from January 1, 1990 to October 6, 2019.

Abbreviations: CHDs, congenital heart defects; ICD, International Classification of Disease; NOS, Newcastle-Ottawa Scale

FIGURE 2. Maternal metabolic disorders and risk of any congenital heart defect in the offspring.

Any CHDs defined as the whole group of heart defects (only including studies that explicitly listed their definition thereof). Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as diagnosed before gestational week 34; and PGDM are defined as DM1 or DM2. All risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2; ¥, BMI ≥ 28 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension; ‡, estimate only for severe CHDs; @, results from singleton pregnancies.

Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

TABLE 1. Summary table of characteristics of included studies

See Table S3 for further details. Details on NOS score can be seen in Table S2.

Abbreviations: DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; PE, preeclampsia; PGDM, pregestational diabetes

medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Any congenital heart defect	Study		
Obesity	Brite et al. [15]	OR	1.26
	Gilboa et al. [31] §£	OR	1.31
	Liu et al. [19] ¤	OR	1.48
	Persson et al. [14] ‡	OR	1.16
	Mills et al. [32]	OR	1.15
	Watkins et al. [37] §€	OR	1.29
	Persson et al. [14] †	PR	1.37
PGDM	Correa et al. [44] §	OR	4.64
	Leirgul et al. [18]	RR	2.92
	Øyen et al. [16]	RR	3.96
	Hoang et al. [17]	PR	3.24
DM1	Chou et al. [46]	OR	2.32
	Liu et al. [19]	OR	4.65
	Ludvigsson et al. [13]	RR	3.19
DM2	Chou et al. [46]	OR	2.85
	Liu et al. [19]	OR	4.12
GDM	Correa et al. [44] §	OR	1.59
	Liu et al. [39]	OR	1.80
	Leirgul et al. [18]	RR	1.47
	Hoang et al. [17]	PR	1.49
Hypertension	Liu et al. [19]	OR	1.81
	Chou et al. [46]	OR	1.87
	Fisher et al. [20] #	OR	1.23
PE (early-onset)	Boyd et al. [21]	OR	7.00
	Brodwall et al. [48] ‡	RR	2.80
	Auger et al. [22] @	PR	5.53
Obesity+GDM	Gilboa et al. [31]	OR	1.82



medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2020.06.25.20140186; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Characteristics	Range of values
Year of publication	1991-2019
Country of study population	North America (n=15), Europe (n=12), Other countries (n=3)
Study design	Cohort (n=17), Case-control (n=13)
Population size	Cohorts (41 013 - 4 207 898), Case-controls (525 - 1 124 370)
Cases with CHDs	Cohorts (233 - 48 249), Case-controls (35 - 10 625)
Included study population	Only live births (n=15); Live births + stillbirths (n=8); Live births + stillbirths + terminated pregnancies (n=7)
Plurality	Singletons (n=13), All (n=8), Not stated (n=9)
Maternal exposure	Obesity (n=15), PGDM (n=9), DM1 (n=4), DM2 (n=2), GDM (n=7), hypertension (n=4), PE (n=3), obesity+GDM (n=1)
Sources of maternal exposure	Registers (n=18), interviews (n=9), medical records (n=2), questionnaire+medical records (n=1)
Newcastle-Ottawa Scale (NOS) score	7 - 8